The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, which is the date by which it intends to take action on the application. The FDA has indicated ...
A novel oral antibiotic zoliflodacin is as effective as ceftriaxone plus azithromycin in treating uncomplicated urogenital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback